Scarica l'app Stockscreener
1.53
2.55%
-0.04
Precedente Chiudi:
$1.57
Aprire:
$1.6
Volume 24 ore:
164.20K
Relative Volume:
2.51
Capitalizzazione di mercato:
$33.61M
Reddito:
-
Utile/perdita netta:
$-27.16M
Rapporto P/E:
-1.0479
EPS:
-1.46
Flusso di cassa netto:
$-25.87M
1 W Prestazione:
+27.50%
1M Prestazione:
+21.35%
6M Prestazione:
-62.77%
1 anno Prestazione:
-19.05%
Intervallo 1D:
$1.51
$1.65
Intervallo di 1 settimana:
$1.19
$1.76
Portata 52W:
$1.15
$4.59
Enlivex Therapeutics Ltd Stock (ENLV) Company Profile
Nome
Enlivex Therapeutics Ltd
Settore
Industria
Telefono
-
Indirizzo
-
Enlivex Therapeutics Ltd Stock (ENLV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-03-02 | Reiterato | H.C. Wainwright | Buy |
Enlivex Therapeutics Ltd Borsa (ENLV) Ultime notizie
ENLV’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - The InvestChronicle
Here's Why We're Watching Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Situation - Simply Wall St
All You Need to Know About Enlivex Therapeutics (ENLV) Rating Upgrade to Buy - Yahoo Finance
Enlivex Announces 2024 Shareholder Meeting - TipRanks
Enlivex Therapeutics (NASDAQ:ENLV) Given Buy Rating at HC Wainwright - Defense World
Enlivex stock poised for growth with key trial readouts by 2025, says H.C. Wainwright - Investing.com India
Enlivex Therapeutics Financials Indicate Net Loss - TipRanks
Enlivex Therapeutics Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - Marketscreener.com
GreenPower and Enlivex Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - AccessWire
GreenPower and Enlivex Interviews to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV - StockTitan
GreenPower and Enlivex Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Yahoo Finance
Enlivex shares rise on EF Hutton's Buy rating By Investing.com - Investing.com Australia
Enlivex shares rise on EF Hutton's Buy rating - Investing.com India
Enlivex Therapeutics (NASDAQ:ENLV) Trading Up 1.9% - Defense World
Enlivex Advances Psoriatic Arthritis Treatment with Allocetra™ - TipRanks
Enlivex Receives Regulatory Authorization For The - GlobeNewswire
Enlivex Receives Regulatory Authorization For The Initiation Of A Phase I Clinical Trial To Evaluate Allocetra In Patients With Psoriatic Arthritis - StockTitan
Enlivex Therapeutics and Biotricity Interviews to Air on the Red - WICZ
Enlivex Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - AccessWire
Enlivex Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Yahoo Finance
CEO Spotlight: Enlivex Therapeutics CEO Tells Why And How Recent - openPR
CEO Spotlight: Enlivex Therapeutics CEO Tells Why And How Recent Milestones Can Transform This MedTech Company ($ENLV) - Barchart
CEO Spotlight: Enlivex Therapeutics CEO Tells Why And How Recent - WICZ
Enlivex Therapeutics (NASDAQ:ENLV) Trading 0.6% Higher - Defense World
Enlivex Commences Key Trial for Thumb Osteoarthritis - TipRanks
Enlivex Announces the Dosing of the First Patient in a - GlobeNewswire
Enlivex Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating ... - Yahoo Finance
Enlivex Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating AllocetraTM in up to 46 Patients with Thumb Osteoarthritis - Yahoo Finance
Enlivex Therapeutics Ltd expected to post a loss of 22 cents a shareEarnings Preview - XM
Enlivex Webinar to Discuss Breakthrough Immunotherapy - TipRanks
Join Enlivex Therapeutics' Chief Executive Officer for a - GlobeNewswire
Join Enlivex Therapeutics' Chief Executive Officer for a Live Investor Webinar and Q&A Session on June 25 - Yahoo Finance
Join Enlivex Therapeutics’ Chief Executive Officer for a Live Investor Webinar and Q&A Session on June 25 - Yahoo Finance
Where Do Analysts Think The Enlivex Therapeutics Ltd (NASDAQ: ENLV) Is Going – Stocks Register - Stocks Register
Enlivex Therapeutics Ltd [ENLV] Is Currently -7.19 below its 200 Period Moving Avg: What Does This Mean? – The ... - The DBT News
Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee ... - Markets Insider
Enlivex’s Allocetra Shows Promise in Osteoarthritis Trial - TipRanks
Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee ... - GlobeNewswire
Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee ... - StockTitan
Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis - Yahoo Finance
Enlivex Therapeutics Reports Q1 FinancialsTipRanks.com - TipRanks
Reviewing Enlivex Therapeutics (NASDAQ:ENLV) and 180 Life Sciences (NASDAQ:ATNF) - Defense World
Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Forecasted to Post Q1 2025 Earnings of ($0.16) Per Share - Defense World
Enlivex Therapeutics (NASDAQ:ENLV) Price Target Cut to $6.00 by Analysts at HC Wainwright - Defense World
Yet Another Biotech Stock Has Found Success During Tuesday's Session - MSN
Enlivex Advances Trial for Thumb Osteoarthritis TherapyTipRanks.com - TipRanks
Enlivex Receives Regulatory Authorization for the Initiation of a Placebo-Controlled Phase I/II Trial Evaluating Allocetra ... - GlobeNewswire
Enlivex Receives Regulatory Authorization for the Initiation of a Placebo-Controlled Phase I/II Trial Evaluating Allocetra ... - Yahoo Finance
Ratios Reveal: Breaking Down Enlivex Therapeutics Ltd (ENLV)'s Financial Health – DWinneX - The Dwinnex
Enlivex Therapeutics Announces New Securities Deal - TipRanks
Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering - GlobeNewswire
Enlivex Therapeutics Ltd Azioni (ENLV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.28%
1.94%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):